Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL

Agenus (AGEN) announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN trial. This study is evaluating Agenus’ immunotherapy combination of botensilimab plus balstilimab versus best supportive care in patients with refractory, unresectable microsatellite stable/mismatch repair proficient metastatic colorectal cancer, a population long considered resistant to immunotherapy. “Enrollment of the first patient in the BATTMAN study marks a key milestone for Agenus and the BOT+BAL program,” said Dr. Steven O’Day, Chief Medical Officer, Agenus. “This study advances our goal of developing effective immunotherapies for patients who currently have few options. We’re grateful to our partners at CCTG, GI Cancer Trials in Australia, and PRODIGE and to the dedicated investigators, site staff, and patients driving this global effort.”